-
Je něco špatně v tomto záznamu ?
Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities
S. Luzzago, C. Palumbo, G. Rosiello, S. Knipper, A. Pecoraro, S. Nazzani, Z. Tian, G. Musi, E. Montanari, SF. Shariat, F. Saad, A. Briganti, O. de Cobelli, PI. Karakiewicz,
Jazyk angličtina Země Nizozemsko
Typ dokumentu srovnávací studie, časopisecké články
NLK
ProQuest Central
od 1999-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2005-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1999-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1999-01-01 do Před 1 rokem
- MeSH
- běloši statistika a číselné údaje MeSH
- černoši nebo Afroameričané statistika a číselné údaje MeSH
- Hispánci a Latinoameričané statistika a číselné údaje MeSH
- karcinom z renálních buněk etnologie mortalita patologie terapie MeSH
- ledviny patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- míra přežití MeSH
- nádory ledvin etnologie mortalita patologie terapie MeSH
- proporcionální rizikové modely MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Geografické názvy
- Itálie MeSH
PURPOSE: To test the association between African-American race and overall mortality (OM) rates in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within the Surveillance, Epidemiology, and End Results registry (2006-2015), we identified patients with clear cell (ccmRCC) and non-clear cell mRCC (non-ccmRCC). African-Americans, Caucasians, and Hispanics were identified. Stratification was made according to histology and treatments: (1) no treatment, (2) systemic therapy (ST), (3) cytoreductive nephrectomy (CNT), (4) CNT + ST. Kaplan-Meier plots and multivariable Cox regression analyses were used. RESULTS: Of ccmRCC patients, 410 (7%), 4353 (75%), and 1005 (17%) were African-American, Caucasian, and Hispanic, respectively. Of non-ccmRCC patients, 183 (25%), 479 (65%), and 77 (10%) were African-American, Caucasian, and Hispanic, respectively. In ccmRCC, African-Americans were associated with higher OM rates (HR 1.20; 95% CI 1.05-1.37). Conversely, in non-ccmRCC, African-Americans were associated with lower OM rates (HR 0.75; 95% CI 0.59-0.97). CONCLUSION: African-American race is associated with prolonged survival in non-ccmRCC, but it is also associated with lower survival rates in ccmRCC. The exception to these observations consisted of patients treated with combination of CNT + ST for either ccmRCC or non-ccmRCC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025159
- 003
- CZ-PrNML
- 005
- 20201222160116.0
- 007
- ta
- 008
- 201125s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10552-020-01270-8 $2 doi
- 035 __
- $a (PubMed)31993859
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Luzzago, Stefano $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. stefanoluzzago@gmail.com. Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy. stefanoluzzago@gmail.com.
- 245 10
- $a Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities / $c S. Luzzago, C. Palumbo, G. Rosiello, S. Knipper, A. Pecoraro, S. Nazzani, Z. Tian, G. Musi, E. Montanari, SF. Shariat, F. Saad, A. Briganti, O. de Cobelli, PI. Karakiewicz,
- 520 9_
- $a PURPOSE: To test the association between African-American race and overall mortality (OM) rates in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within the Surveillance, Epidemiology, and End Results registry (2006-2015), we identified patients with clear cell (ccmRCC) and non-clear cell mRCC (non-ccmRCC). African-Americans, Caucasians, and Hispanics were identified. Stratification was made according to histology and treatments: (1) no treatment, (2) systemic therapy (ST), (3) cytoreductive nephrectomy (CNT), (4) CNT + ST. Kaplan-Meier plots and multivariable Cox regression analyses were used. RESULTS: Of ccmRCC patients, 410 (7%), 4353 (75%), and 1005 (17%) were African-American, Caucasian, and Hispanic, respectively. Of non-ccmRCC patients, 183 (25%), 479 (65%), and 77 (10%) were African-American, Caucasian, and Hispanic, respectively. In ccmRCC, African-Americans were associated with higher OM rates (HR 1.20; 95% CI 1.05-1.37). Conversely, in non-ccmRCC, African-Americans were associated with lower OM rates (HR 0.75; 95% CI 0.59-0.97). CONCLUSION: African-American race is associated with prolonged survival in non-ccmRCC, but it is also associated with lower survival rates in ccmRCC. The exception to these observations consisted of patients treated with combination of CNT + ST for either ccmRCC or non-ccmRCC.
- 650 _2
- $a černoši nebo Afroameričané $x statistika a číselné údaje $7 D001741
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a karcinom z renálních buněk $x etnologie $x mortalita $x patologie $x terapie $7 D002292
- 650 _2
- $a běloši $x statistika a číselné údaje $7 D044465
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a Hispánci a Latinoameričané $x statistika a číselné údaje $7 D006630
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $x patologie $7 D007668
- 650 _2
- $a nádory ledvin $x etnologie $x mortalita $x patologie $x terapie $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 _2
- $a míra přežití $7 D015996
- 651 _2
- $a Itálie $x epidemiologie $7 D007558
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Palumbo, Carlotta $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy.
- 700 1_
- $a Rosiello, Giuseppe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- 700 1_
- $a Knipper, Sophie $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- 700 1_
- $a Pecoraro, Angela $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.
- 700 1_
- $a Nazzani, Sebastiano $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. Academic Department of Urology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy.
- 700 1_
- $a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
- 700 1_
- $a Musi, Gennaro $u Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy.
- 700 1_
- $a Montanari, Emanuele $u Department of Urology, IRCCS Fondazione Ca' Granda-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Departments of Urology, Weill Cornell Medical College, New York, NY, USA. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 700 1_
- $a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
- 700 1_
- $a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- 700 1_
- $a de Cobelli, Ottavio $u Department of Urology, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti, 435, 20141, Milan, Italy. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.
- 773 0_
- $w MED00001035 $t Cancer causes & control : CCC $x 1573-7225 $g Roč. 31, č. 3 (2020), s. 263-272
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31993859 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160112 $b ABA008
- 999 __
- $a ok $b bmc $g 1599304 $s 1115845
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 31 $c 3 $d 263-272 $e 20200128 $i 1573-7225 $m Cancer causes & control $n Cancer Causes Control $x MED00001035
- LZP __
- $a Pubmed-20201125
